Bioverativ

fiercebiotech | September 06, 2017

Biogen’s newly spun off hemophilia biotech Bioverativ has signed a new pact with U.K. biotech Bicycle Therapeutics. The pair will ride tandem on new research work for hemophilia and sickle cell disease with the help of the biotech’s bicyclic peptide platform (the eponymous Bicycle). Bicycles combine attributes of antibodies, small molecules and peptides within one molecule, which the company says should allow “high selectivity and affinity” while at the same time being ab...

Biogen | November 15, 2016

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. The planned spin-off of Bioverativ is expected to be completed on February 1, 2017....

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...